Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …

Background International guidelines have endorsed the use of edoxaban or rivaroxaban as
an alternative to low-molecular-weight heparin (LMWH) for the treatment of acute venous …

Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

Background Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐
associated venous thromboembolism (VTE). While apixaban is approved for the treatment of …

Background Recent guidelines recommend consideration of the use of oral edoxaban or
rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However …

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant
numbers of patients with hematological cancers. While these unique immunotherapies have …

Background Direct oral anticoagulants are recommended for the treatment of cancer-
associated thrombosis (CAT) as an alternative to low-molecular-weight heparin (LMWH), but …

Systemic cancer and ischemic stroke are common conditions and two of the most frequent
causes of death among the elderly. The association between cancer and stroke has been …

Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous
thromboembolism (VTE) and major bleeding complications. Risks vary significantly between …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that continues to
be challenging to treat. PDAC has the lowest 5‐year relative survival rate compared with all …